MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 38.9% in March

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 980,100 shares, a growth of 38.9% from the February 28th total of 705,700 shares. Based on an average trading volume of 352,300 shares, the short-interest ratio is currently 2.8 days. Currently, 8.0% of the company’s shares are sold short.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP purchased a new stake in shares of MIRA Pharmaceuticals in the 4th quarter valued at $28,000. International Assets Investment Management LLC acquired a new stake in MIRA Pharmaceuticals during the fourth quarter worth approximately $29,000. Northern Trust Corp increased its position in shares of MIRA Pharmaceuticals by 50.9% during the fourth quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock worth $35,000 after purchasing an additional 10,238 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of MIRA Pharmaceuticals in the 4th quarter valued at $52,000. Finally, Virtu Financial LLC acquired a new stake in shares of MIRA Pharmaceuticals during the fourth quarter worth about $72,000. Hedge funds and other institutional investors own 35.16% of the company’s stock.

MIRA Pharmaceuticals Trading Down 2.6 %

Shares of NASDAQ:MIRA traded down $0.03 on Tuesday, reaching $0.96. The company had a trading volume of 124,921 shares, compared to its average volume of 1,917,603. The firm’s 50 day simple moving average is $1.12 and its 200-day simple moving average is $1.22. MIRA Pharmaceuticals has a 52-week low of $0.51 and a 52-week high of $5.01. The firm has a market capitalization of $15.82 million, a PE ratio of -1.71 and a beta of 2.31.

MIRA Pharmaceuticals (NASDAQ:MIRA) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.14. As a group, equities research analysts predict that MIRA Pharmaceuticals will post -0.6 earnings per share for the current year.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.